
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is poised for significant growth, with a projected revenue of $5.83 billion in 2025, reflecting a 9.2% year-over-year underlying increase, including a $4.27 billion contribution from transcatheter aortic valve replacement (TAVR) sales. The company's performance in Q4 indicates strong demand, with TAVR sales reaching $1.04 billion, marking a 9.3% year-over-year underlying growth, while TMTT sales showcased remarkable growth of 85% year-over-year on an ex-FX basis. Furthermore, Edwards Lifesciences anticipates the global transcatheter mitral and tricuspid therapies (TMTT) market will expand to $5 billion, highlighting robust long-term growth potential in this segment.
Bears say
Edwards Lifesciences is facing a negative outlook due to projected Q1 2025 growth rates for total company sales and TAVR technologies falling below the low end of the firm's guidance ranges, largely attributed to having one less selling day in the quarter. Additionally, multiple external factors, such as macroeconomic conditions, competition, and challenges in market penetration, are expected to hinder revenue growth, while foreign exchange impacts are anticipated to create a significant headwind of approximately $130 million. Overall, these dynamics are contributing to a projection suggesting a decline in stock performance, as indicated by the downside scenario analysis based on future price-to-earnings ratios.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares